1.33
+0.76%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NanoViricides,
From its filings with the US Securities and Exchange Commission
NanoViricides, is based in Shelton, Connecticut and is incorporated in Delaware. Its shares trade on NYSE under the ticker NNVC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported revenue of $0 and a net loss of $8.2m. At that date it held total assets of $9.9m and shareholders' equity of $8.7m.
On September 25, 2013, the Company’s common stock began trading on the New York Stock Exchange American under the symbol, “NNVC”.
We are a clinical stage company. Phase II clinical trials of our first drug, NV-387, has previously successfully completed a Phase Ia/Ib clinical trial for human clinical safety and tolerability, wherein the drug was found to be safe and well tolerated, with no reportable adverse events, and no subjects dropping out.. Additionally, drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.
We are engaged in developing a class of drugs, that we call nanoviricides™, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. This approach enables rapid development of effective new drugs against a number of different viruses, that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses. In contrast, viruses readily escape vaccines, antibodies and small chemical drugs developed using the traditional antiviral approaches because, generally speaking, a small number of mutations allow the virus to become resistant, and thereupon resistant viruses can continue to grow and expand.
Quoted from its 10-K, filed 28 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Aug 2004
- Employees
- 7
- Website
- nanoviricides.com ↗
- Head office
- 1 CONTROLS DRIVE, SHELTON, CT, 06484
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Anil DiwanPresident, Chief Executive Officer, Executive Chairman of the Board, since 2005$432,498
- Ms. Meeta VyasChief Financial Officer$135,507
- Dr. Makarand JawadekarIndependent Director$40,000
- Mr. Theodore RokitaIndependent Director$40,000
- Mr. Brian ZuckerIndependent Director$40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NanoViricides Inc has a strong scientific expertise in nanomedicine technology with a focus on developing novel antiviral therapies.
- The company's proprietary nanoviricide platform offers potential advantages in terms of molecular construction, antiviral efficacy, and delivery mechanisms.
Weaknesses
- NanoViricides Inc currently operates with a relatively small team, which might limit their ability to rapidly advance research and development projects.
- The company's success relies heavily on the approval and adoption of their experimental drugs, which carries inherent risks and uncertainties.
Opportunities
- The global demand for effective antiviral therapeutics is on the rise, presenting an opportunity for NanoViricides Inc to gain market share and generate revenue.
- The ongoing advancements in nanotechnology and its applications in medicine provide the company with potential collaborations and partnerships.
Threats
- NanoViricides Inc faces significant competition from established pharmaceutical companies and other players in the antiviral drug development space.
- Regulatory hurdles and stringent approval processes pose a threat to the company's ability to bring their drugs to market in a timely manner.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.